Spread of Extended-Spectrum β-Lactamase CTX-M-Producing Escherichia coli Clinical Isolates in Community and Nosocomial Environments in Portugal

Antimicrobial Agents and Chemotherapy
2007.0

Abstract

Of the 181 unduplicated Escherichia coli strains isolated in nine different hospitals in three Portuguese regions, 119 were extended-spectrum beta-lactamase (ESBL)-CTX-M producers and were selected for phenotype and genotype characterization. CTX-M producer strains were prevalent among community-acquired infections (56%), urinary tract infections (76%), and patients >/=60 years old (76%). In MIC tests, all strains were resistant to cefotaxime, 92% were resistant to ceftazidime, 93% were resistant to quinolones, 89% were resistant to aminoglycoside, and 26% were resistant to trimethoprim-sulfamethoxazole; all strains were sensitive to carbapenems, and 92% of the strains had a multidrug resistance phenotype. Molecular methods identified 109 isolates harboring a bla(CTX-M-15) gene, 1 harboring the bla(CTX-M-32) gene (first identification in the country), and 9 harboring the bla(CTX-M-14) gene. All isolates presented the ISEcp1 element upstream from the bla(CTX-M) genes; one presented the IS903 element (downstream of bla(CTX-M-14) gene), and none had the IS26 element; 85% carried bla(TEM-1B), and 84% also carried a bla(OXA-30). Genetic relatedness analysis based on pulsed-field gel electrophoresis defined five clusters and indicated that 76% of all isolates (from cluster IV) corresponded to a single epidemic strain. Of the 47 strains from one hospital, 41 belonged to cluster IV and were disseminated in three main wards. CTX-M-producing E. coli strains are currently a problem in Portugal, with CTX-M-15 particularly common. This study suggests that the horizontal transfer of bla(CTX-M) genes, mediated by plasmids and/or mobile elements, contributes to the dissemination of CTX-M enzymes to community and hospital environments. The use of extended-spectrum cephalosporins, quinolones, and aminoglycosides is compromised, leaving carbapenems as the therapeutic option for severe infections caused by ESBL producers.

Knowledge Graph

Similar Paper

Spread of Extended-Spectrum β-Lactamase CTX-M-Producing Escherichia coli Clinical Isolates in Community and Nosocomial Environments in Portugal
Antimicrobial Agents and Chemotherapy 2007.0
Molecular Characterization and Epidemiology of Extended-Spectrum- β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic
Antimicrobial Agents and Chemotherapy 2008.0
Molecular Characteristics of Travel-Related Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from the Calgary Health Region
Antimicrobial Agents and Chemotherapy 2009.0
Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania
Antimicrobial Agents and Chemotherapy 2009.0
bla <sub>CTX-M</sub> Genes in Escherichia coli Strains from Croatian Hospitals Are Located in New ( bla <sub>CTX-M-3a</sub> ) and Widely Spread ( bla <sub>CTX-M-3a</sub> and bla <sub>CTX-M-15</sub> ) Genetic Structures
Antimicrobial Agents and Chemotherapy 2009.0
Nationwide Survey of CTX-M-Type Extended-Spectrum β-Lactamases among Klebsiella pneumoniae Isolates in Slovenian Hospitals
Antimicrobial Agents and Chemotherapy 2009.0
Rapid Dissemination and Diversity of CTX-M Extended-Spectrum β-Lactamase Genes in Commensal Escherichia coli Isolates from Healthy Children from Low-Resource Settings in Latin America
Antimicrobial Agents and Chemotherapy 2007.0
Extended-Spectrum β-Lactamases of the CTX-M Type Now in Switzerland
Antimicrobial Agents and Chemotherapy 2007.0
First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System
Antimicrobial Agents and Chemotherapy 2007.0
High Prevalence of CTX-M-Type β-Lactamases among Clinical Isolates of Enterobacteriaceae in Bamako, Mali
Antimicrobial Agents and Chemotherapy 2009.0